Monopar Therapeutics
ALXN1840
Wilson disease
Resolved
80days ago
Phase 3 readout · Apr 18, 2026
What's at stake
Phase 3 trial results for ALXN1840 in Wilson disease are due Apr 18, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“These findings support the continued advancement of ALXN1840 toward the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026.”